Combination treatment with captopril and the thyroid hormone analogue 3,5-diiodothyropropionic acid: A new approach to improving left ventricular performance in heart failure

Circulation

Volumn 88, Issue 3, 1993, Pages 1289-1298

  Pennock, Gregory D ^a   Raya, Thomas E ^a   Bahl, Joseph J ^a   Goldman, Steven ^a   Morkin, Eugene ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b University Medical Center   (United States)

Author keywords

Cardiotonic agents; Heart failure; Thyroid

Indexed keywords

3,5 DIIODOTHYROPROPIONIC ACID; CAPTOPRIL; THYROID HORMONE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEMODYNAMICS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR RESISTANCE;

ANIMAL; CAPTOPRIL; COMPARATIVE STUDY; DIIODOTHYRONINES; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HEMODYNAMICS; MALE; MYOCARDIAL INFARCTION; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VENTRICULAR FUNCTION, LEFT;

EID: 0027199125     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.88.3.1289     Document Type: Article

References (59)

1. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
4. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987;75:331-339.
5. Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol. 1988;12:1299-1317.
6. Sasayama S. What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther. 1992;6:15-18.
7. Rubin SA, Tabak L. MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure. J Am Coll Cardiol. 1985;5:1422-1427.
8. Shah PK, Amin DK, Hulse S, Shellock F, Swan HJC. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. Circulation. 1985;71: 326-331.
9. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA, for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation. 1990; 82:774-780.
10. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group. Effects of oral milrinone on mortality in chronic heart failure. N Engl J Med. 1991;325: 1468-1475.
11. Morkin E, Flink IL, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovasc Dis. 1983;25:435-464.
12. Gay RG, Raya TE, Lancaster LD, Lee RW, Morkin E, Goldman S. Effects of thyroid state on venous compliance and left ventricular performance in rats. Am J Physiol. 1988;254(Heart Circ Physiol 23):H81-H88.
13. Goldman S, Olajos M, Morkin E. Control of cardiac output in thyrotoxic calves: evaluation of changes in the systemic circulation. J Clin Invest. 1984;73:358-365.
14. Gay R, Lee RW, Appleton C, Olajos M, Martin GV, Morkin E, Goldman S. Control of cardiac function and venous return in thyrotoxic calves. Am J Physiol. 1987;252(Heart Circ Physiol 21): H467-H473.
15. Buccino RA, Spann JF, Pool PE, Sonnenblick EH, Braunwald E. Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest. 1967; 46:1669-1682.
16. + depolarization. Biochem J. 1990;268:563-569.
17. MacKinnon R, Morgan JP. Influence of the thyroid state on the calcium transient in ventricular muscle. Pflugers Arch. 1986;407: 142-144.
18. MacKinnon R, Gwathmey JK, Allen PD, Briggs GM, Morgan JP. Modulation by the thyroid state of intracellular calcium and contractility in ferret ventricular muscle. Circ Res. 1988;63:1080-1089.
19. Samuels HH, Forman BM, Horowitz ZD, Ye Z-S. Regulation of gene expression by thyroid hormone. J Clin Invest. 1988;81:957-967.
20. Evans R. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889-895.
21. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990;88:626-630.
22. Gay RG, Graham S, Aguirre M, Goldman S, Morkin E. Effects of 10-to 12-day treatment with L-thyroxine in rats with myocardial infarction. Am J Physiol. 1988;255(Heart Circ Physiol 24):H801-H806.
23. Stasilli WR, Kroc RL, Meltzer RI. Antigoitrogenic and calorigenic activities of thyroxine analogues in rats. Endocrinology. 1959;64: 62-82.
24. Pennock GD, Raya TE, Bahl JJ, Goldman S, Morkin E. Cardiac effects of 3,5 -diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther. 1992;263:163-169.
25. Gay R, Gustafson TA, Goldman S, Morkin E. Effects of L-thyroxine in rats with chronic heart failure after myocardial infarction. Am J Physiol 1987;253(Heart Circ Physiol 22): H341-H346.
26. Gay RG, Wool S, Faquin M, Goldman S. Total vascular pressure-volume relationship in conscious rats with chronic heart failure. Am J Physiol. 1986;251(Heart Circ Physiol 20):H483-H489.
27. Raya TE, Gay RG, Lancaster L, Aguirre M, Moffett C, Goldman S. Serial changes in left ventricular relaxation and chamber stiffness after large myocardial infarction in rats. Circulation. 1988; 77:1424-1431.
28. Pfeffer MA, Pfeffer J, Fishbein M, Fletcher P, Spadaro J, Kloner R, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979;44:503-512.
29. Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction: effects on systolic function. Circ Res. 1981;49:618-626.
30. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985;57:84-95.
31. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72:406-412.
32. Raya TE, Gay RG, Aguirre M, Goldman S. Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res. 1989;64:330-333.
33. Hutter JF, Piper HM, Spieckermann PG. An index for estimation of oxygen consumption in rat heart by hemodynamic parameters. Am J Physiol. 1985;249(Heart Circ Physiol 18):H729-H734.
34. Zar JH. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall; 1974:133-139,151-155.
35. Guyton AC, Jones CE, Coleman TG. Circulatory Physiology: Cardiac Output and Its Regulation. Philadelphia, Pa: WB Saunders Co; 1973.
36. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation. 1990;81(suppl III):III-1-III-7.
37. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure. N Engl J Med. 1977;297:27-31.
38. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61:70-76.
39. Beuckelmann DJ, Näbauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992;85:1046-1055.
40. Kim D, Smith TW. Effects of thyroid hormone on sodium pump sites, sodium content and contractile response to cardiac glycosides in cultured chick ventricular cells. J Clin Invest. 1984;74: 1481-1488.
41. 2+-ATPaSe gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990;85:305-309.
42. Brillantes AM, Allen P, Takahashi T, Izumo S, Marks A. Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res. 1992;71:18-26.
43. 2+-ATPase gene. Circ Res. 1992;71:1357-1365.
44. 2+-ATPaSe gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res. 1990;66:554-564.
45. 2+-ATPase in the rat heart. J Biol Chem. 1988;263:6941-6944.
46. Arai M, Otsu K, MacLennan DH, Alpert NR, Periasamy M. Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins. Circ Res. 1991;69:266-276.
47. Morkin E. Regulation of cardiac myosin heavy chain genes in the heart. Circulation. 1993;87:1451-1460.
48. Williams LT, Lefkowitz RJ, Watanabe AM, Hathaway DR, Besh HR Jr. Thyroid hormone regulation of β-adrenergic receptor number. J Biol Chem. 1977;252:2787-2789.
49. Ciaraldi T, Marinetti GV. Thyroxine and propylthiouracil effects in vivo on alpha- and beta-adrenergic receptors in rat heart. Biochem Biophys Res Commun. 1977;74:984-991.
50. Liggett SB, Shah SD, Cryer PE. Increased fat and skeletal muscle β-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis. J Clin Invest. 1989;83:803-809.
51. Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on α- and β-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev. 1983;4:378-388.
52. Goldman S, Olajos M, Pieniaszek H, Perrier D, Mayersohn M, Morkin E. Beta-adrenergic blockade with propranolol in conscious euthyroid and thyrotoxic calves: dosage requirements and effects on heart rate and left ventricular performance. J Pharmacol Exp Ther. 1981;219:394-399.
53. Bedotto JB, Gay RG, Graham SD, Morkin E, Goldman S. Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade. J Pharmacol Exp Ther. 1989;248:632-636.
54. Levine MA, Feldman AM, Robishaw JD, Ladenson PW, Ahn TG, Moroney JF, Smallwood PM. Influence of thyroid hormone status on expression of genes encoding G protein subunits in the rat heart. J Biol Chem. 1990;265:3553-3560.
55. Litwin SE, Litwin CM, Raya TE, Warner A, Goldman S. Contractility and stiffness of noninfarcted myocardium following coronary ligation in rats: effects of chronic angiotensin converting enzyme inhibition. Circulation. 1991;83:1028-1037.
56. Conn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study. N Engl J Med. 1986;314:1547-1552.
57. Strauer BE, Scherpe A. Experimental hyperthyroidism: IV. Myocardial muscle mechanics and oxygen consumption in eu- and hyperthyroidism. Basic Res Cardiol. 1975;70:246-255.
58. Hoch FL. Thyrotoxicosis as a disease of mitochondria. N Engl J Med. 1962;266:446-454.
59. Hoch FL. Biochemical actions of thyroid hormones. Physiol Rev. 1962;42:605-673.